Scott has led our research team since 2007 and has served as vice president of research since 2011. Previously, he was the director of the Chemical Biology Platform at the Broad Institute, directing a multi-disciplinary team of professional scientists and technicians in the fields of synthetic chemistry, analytical chemistry, high-throughput screening, computational science, and software engineering. This interdisciplinary organization is closely affiliated with the laboratory of Stuart Schreiber from Harvard University and is one of the largest and oldest academic screening centers in the country. Prior to joining the Broad Institute, Scott worked at Millennium Pharmaceuticals, where he managed scientific teams in cell biology, molecular biology, neuroscience, and bioinformatics for a large-scale genomics-based drug discovery program. Earlier in his career, Scott was at Neurocrine Biosciences, where he played a key role in the exploration of glutamate transporters in the field of stroke and neurological disorders.
Scott earned his B.S. from MIT in Electrical Engineering, Ph.D. from the University of California at Berkeley in Neuroscience, and completed his post-doctoral fellowship at the Vollum Institute in Portland, Oregon.
Oliver has served as our President and Chief Executive Officer and as a member of our board of directors since 2009. From July 2004 until September 2007, Dr. Fetzer served as Senior Vice President, Corporate Development and Research & Development at Cubist Pharmaceuticals, Inc. From January 2003 to July 2004, he served as Cubist Pharmaceuticals, Inc.’s Senior Vice President, Corporate Development and Chief Business Officer and, from July 2002 until January 2003, he served as its Senior Vice President, Business Development. Before his time at Cubist Pharmaceuticals, Inc., commencing in 1993, Dr. Fetzer held various positions of increasing responsibility at the Boston Consulting Group (BCG), a global leading management consulting firm, including Consultant, Project Leader, Principal, and Partner and Managing Director. Since December 2005, Dr. Fetzer has served on the board of directors of Auxilium Pharmaceuticals, Inc. and since April 2011 on the board of Tecan Group AG.
Oliver received a B.S. in Biochemistry from the College of Charleston, his Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina and an M.B.A. from Carnegie Mellon University.
Edward has served as our Chief Medical Officer and Senior Vice President since 2011. Prior to joining Cerulean, Dr. Garmey held a variety of positions at ArQule, Inc., a clinical-stage biotechnology company, including as Vice President for Clinical Development since 2008, and as Clinical Development Liaison from 2007 to 2008. From 2006 to 2007, Dr. Garmey served as Medical Director at GPC Biotech, a German biopharmaceutical company and now a subsidiary of Agennix AG, where he helped oversee global clinical development studies.
Dr. Garmey received his A.B. from Harvard University and his M.D. from New York University. He is a member of the Scientific Advisory Board for the Harvard-MIT Broad Institute’s Cancer Vaccine Initiative, and he serves on the Board of Visitors of Hearth, a Boston-based non-profit organization dedicated to the elimination of homelessness among the elderly.
Chris has served as our Senior Vice President and Chief Business Officer since 2012. Prior to that, Mr. Guiffre held a number of senior executive positions at various biopharmaceutical companies. From 2010 to 2012, he served as President and Chief Executive Officer of Alvos Therapeutics, Inc.; from 2008 to 2009, he served as Chief Business Officer at Hydra Biosciences, Inc.; and from 2001 to 2008, he served as a senior executive at Cubist Pharmaceuticals, Inc., most recently as Senior Vice President, General Counsel and Secretary. From 1997 to 2001, Mr. Guiffre held several positions at Renaissance Worldwide, Inc., including Vice President, General Counsel and Clerk. Prior to that, he was an Associate at Bingham, Dana & Gould LLP (now known as Bingham McCutchen LLP).
Chris received a B.S. degree from Babson College, a J.D. from Boston College Law School, and an M.B.A. from Boston College Carroll School of Management.
Karen has served as our Senior Vice President, Finance and Administration since 2010. Prior to joining Cerulean, from 2001 to 2009, Ms. Roberts served as Vice President, Finance and Administration of Elixir Pharmaceuticals, Inc., a biopharmaceutical company where she was the senior financial executive responsible for all aspects of finance, accounting and administration. From 1998 to 2001, Ms. Roberts served in a number of roles, including Corporate Controller and Chief Accounting Officer and Vice President, Finance, at Frontline Group, Inc., a provider of business performance improvement services and products. Prior to that, Ms. Roberts served as Director of Finance at Dyax Corp., a biotechnology company, and as Corporate Controller and Director, Financial Administration at T Cell Sciences, Inc., a biopharmaceutical company.
Ms. Roberts received her B.S. in Business Administration with a concentration in accounting from Salem State College.
Marc has led our analytical team since 2007 and has served as vice president of pharmaceutical sciences and manufacturing since 2011. Previously, he was senior director of quality at Momenta Pharmaceuticals, where he was responsible for building the quality affairs and quality control functions, including the establishment of an in-house cGMP testing laboratory. Prior to joining Momenta, he held various CMC related positions ranging from analytical development, QA/QC, production technology, and regulatory affairs at Millennium Pharmaceuticals, Biogen, and Boehringer Ingelheim.
Marc earned a BS degree in Biology from Pennsylvania State University and a MS degree in Chemistry from Montclair State University.